3 documents found, page 1 of 1
Impact of Preoperative Chemotherapy Features on Patient Outcomes after Hepatect...
Innominato, P; Cailliez, V; Allard, MA; Lopez-Ben, S; Ferrero, A; Pinto Marques, H; Hubert, C; Giuliante, F; Pereira, F; Cugat, E; Mirza, DBackground: Prognostic factors have been extensively reported after resection of colorectal liver metastases (CLM); however, specific analyses of the impact of preoperative systemic anticancer therapy (PO-SACT) features on outcomes is lacking. Methods: For this real-world evidence study, we used prospectively collected data within the international surgical LiverMetSurvey database from all patients with initial...
Early tumour response as a survival predictor in previously- treated patients r...
Bouchahda, M; Boige, V; Smith, D; Karaboué, A; Ducreux, M; Hebbar, M; Lepére, C; Focan, C; Guimbaud, R; Innominato, P; Awad, S; Carvalho, CBACKGROUND: Surgery for colorectal liver metastases results in an overall survival of about 40% at 5 years. Progression-free survival is increased with the addition of oxaliplatin and fluorouracil chemotherapy. The addition of cetuximab to these chemotherapy regimens results in an overall survival advantage in patients with advanced disease who have the KRAS exon 2 wild-type tumour genotype. We aimed to assess ...
Conversion to resection of liver metastases from colorectal cancer with hepatic...
Lévi, FA; Boige, V; Hebbar, M; Smith, D; Lepère, C; Focan, C; Karaboué, A; Guimbaud, R; Carvalho, C; Tumolo, S; Innominato, P; Ajavon, Y; Truant, SBACKGROUND: Systemic chemotherapy typically converts previously unresectable liver metastases (LM) from colorectal cancer to curative intent resection in ∼15% of patients. This European multicenter phase II trial tested whether hepatic artery infusion (HAI) with triplet chemotherapy and systemic cetuximab could increase this rate to 30% in previously treated patients. PATIENTS AND METHODS: Participants had unre...